Twist Bioscience Corporation Operating Income
Twist Bioscience Corporation (TWST) reported Operating Income of -$36.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-03
- Twist Bioscience Corporation operating income (loss) for the quarter ending 2026-06-30 was -$36.28M.
- Twist Bioscience Corporation operating income (loss) for the quarter ending 2026-03-31 was -$45.86M.
- Twist Bioscience Corporation operating income (loss) for the quarter ending 2025-12-31 was -$32.90M.
- Twist Bioscience Corporation operating income (loss) for the quarter ending 2025-09-30 was -$29.93M.
- Twist Bioscience Corporation operating income (loss) for fiscal 2025 was -$136.26M.
- Twist Bioscience Corporation operating income (loss) for fiscal 2024 was -$220.83M.
- Twist Bioscience Corporation operating income (loss) for fiscal 2023 was -$217.16M.
- Twist Bioscience Corporation operating income (loss) for fiscal 2022 was -$234.78M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$36.28M 10-Q · filed 2026-08-03 | -$82.14M derived: sum of 2 quarters · filed 2026-08-03 | -$115.04M 10-Q · filed 2026-08-03 | -$144.98M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$45.86M 10-Q · filed 2026-05-04 | -$78.76M 10-Q · filed 2026-05-04 | -$108.70M derived: sum of 3 quarters · filed 2026-05-04 | -$138.82M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$32.90M 10-Q/A · filed 2026-02-26 | -$62.83M derived: sum of 2 quarters · filed 2026-02-26 | -$92.95M derived: sum of 3 quarters · filed 2026-08-03 | -$134.51M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-09-30 | -$29.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | -$60.05M derived: sum of 2 quarters · filed 2026-08-03 | -$101.61M derived: sum of 3 quarters · filed 2026-08-03 | -$136.26M 10-K · filed 2025-11-17 |
| 2025-06-30 | -$30.12M 10-Q · filed 2026-08-03 | -$71.68M derived: sum of 2 quarters · filed 2026-08-03 | -$106.33M 10-Q · filed 2026-08-03 | -$142.37M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$41.56M 10-Q · filed 2026-05-04 | -$76.20M 10-Q · filed 2026-05-04 | -$112.25M derived: sum of 3 quarters · filed 2026-05-04 | -$201.17M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$34.64M 10-Q/A · filed 2026-02-26 | -$70.69M derived: sum of 2 quarters · filed 2026-02-26 | -$159.61M derived: sum of 3 quarters · filed 2026-02-26 | -$208.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-09-30 | -$36.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | -$124.97M derived: sum of 2 quarters · filed 2025-11-17 | -$173.85M derived: sum of 3 quarters · filed 2025-11-17 | -$220.83M 10-K · filed 2025-11-17 |
| 2024-06-30 | -$88.92M 10-Q · filed 2025-08-04 | -$137.81M derived: sum of 2 quarters · filed 2025-08-04 | -$184.79M 10-Q · filed 2025-08-04 | -$234.90M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-03-31 | -$48.89M 10-Q · filed 2025-05-05 | -$95.87M 10-Q · filed 2025-05-05 | -$145.98M derived: sum of 3 quarters · filed 2025-11-17 | -$206.76M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-12-31 | -$46.98M 10-Q · filed 2025-02-03 | -$97.09M derived: sum of 2 quarters · filed 2025-11-17 | -$157.87M derived: sum of 3 quarters · filed 2025-11-17 | -$219.51M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-09-30 | -$50.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | -$110.89M derived: sum of 2 quarters · filed 2025-11-17 | -$172.53M derived: sum of 3 quarters · filed 2025-11-17 | -$217.16M 10-K · filed 2025-11-17 |
| 2023-06-30 | -$60.78M 10-Q · filed 2024-08-02 | -$122.42M derived: sum of 2 quarters · filed 2024-08-02 | -$167.05M 10-Q · filed 2024-08-02 | -$223.92M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | -$61.64M 10-Q · filed 2024-05-02 | -$106.27M 10-Q · filed 2024-05-02 | -$163.14M derived: sum of 3 quarters · filed 2024-11-18 | -$224.30M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | -$44.63M 10-Q · filed 2024-02-02 | -$101.50M derived: sum of 2 quarters · filed 2024-11-18 | -$162.66M derived: sum of 3 quarters · filed 2024-11-18 | -$223.47M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-09-30 | -$56.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | -$118.03M derived: sum of 2 quarters · filed 2024-11-18 | -$178.84M derived: sum of 3 quarters · filed 2024-11-18 | -$234.78M 10-K · filed 2024-11-18 |
| 2022-06-30 | -$61.16M 10-Q · filed 2023-08-07 | -$121.97M derived: sum of 2 quarters · filed 2023-08-07 | -$177.91M 10-Q · filed 2023-08-07 | -$217.72M derived: sum of 4 quarters · filed 2023-11-21 |
| 2022-03-31 | -$60.80M 10-Q · filed 2023-05-08 | -$116.74M 10-Q · filed 2023-05-08 | -$156.55M derived: sum of 3 quarters · filed 2023-11-21 | -$198.67M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-12-31 | -$55.94M 10-Q · filed 2023-02-07 | -$95.75M derived: sum of 2 quarters · filed 2023-11-21 | -$137.87M derived: sum of 3 quarters · filed 2023-11-21 | -$175.87M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-09-30 | -$39.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | -$81.93M derived: sum of 2 quarters · filed 2023-11-21 | -$119.93M derived: sum of 3 quarters · filed 2023-11-21 | -$152.73M 10-K · filed 2023-11-21 |
| 2021-06-30 | -$42.12M 10-Q · filed 2022-08-08 | -$80.12M derived: sum of 2 quarters · filed 2022-08-08 | -$112.92M 10-Q · filed 2022-08-08 | -$136.88M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | -$38.00M 10-Q · filed 2022-05-06 | -$70.80M 10-Q · filed 2022-05-06 | -$94.76M derived: sum of 3 quarters · filed 2023-06-05 | -$122.96M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | -$32.79M 10-Q · filed 2022-02-09 | -$56.76M derived: sum of 2 quarters · filed 2023-06-05 | -$84.96M derived: sum of 3 quarters · filed 2023-06-05 | -$117.04M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | -$23.97M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | -$52.16M derived: sum of 2 quarters · filed 2023-06-05 | -$84.25M derived: sum of 3 quarters · filed 2023-06-05 | -$140.08M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | -$28.20M 10-Q · filed 2021-08-09 | -$60.28M derived: sum of 2 quarters · filed 2021-08-09 | -$116.11M 10-Q · filed 2021-08-09 | -$147.68M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | -$32.09M 10-Q · filed 2021-05-07 | -$87.92M 10-Q · filed 2021-05-07 | -$119.48M derived: sum of 3 quarters · filed 2021-11-23 | -$147.60M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | -$55.83M 10-Q · filed 2021-02-09 | -$87.40M derived: sum of 2 quarters · filed 2021-11-23 | -$115.52M derived: sum of 3 quarters · filed 2021-11-23 | -$141.78M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | -$31.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | -$59.69M derived: sum of 2 quarters · filed 2021-11-23 | -$85.95M derived: sum of 3 quarters · filed 2021-11-23 | -$108.85M 10-K · filed 2021-11-23 |
| 2019-06-30 | -$28.12M 10-Q · filed 2020-08-12 | -$54.38M derived: sum of 2 quarters · filed 2020-08-12 | -$77.28M 10-Q · filed 2020-08-12 | -$96.98M derived: sum of 4 quarters · filed 2020-11-27 |
| 2019-03-31 | -$26.26M 10-Q · filed 2020-05-13 | -$49.16M 10-Q · filed 2020-05-13 | -$68.86M derived: sum of 3 quarters · filed 2020-11-27 | -$86.35M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-12-31 | -$22.90M 10-Q · filed 2020-02-10 | -$42.60M derived: sum of 2 quarters · filed 2020-11-27 | -$60.09M derived: sum of 3 quarters · filed 2020-11-27 | -$76.70M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-09-30 | -$19.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-27 | -$37.19M derived: sum of 2 quarters · filed 2020-11-27 | -$53.81M derived: sum of 3 quarters · filed 2020-11-27 | -$70.56M 10-K · filed 2020-11-27 |
| 2018-06-30 | -$17.49M 10-Q · filed 2019-08-09 | -$34.10M derived: sum of 2 quarters · filed 2019-08-09 | -$50.85M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | -$16.62M 10-Q · filed 2019-05-02 | -$33.37M 10-Q · filed 2019-05-02 | ||
| 2017-12-31 | -$16.75M 10-Q · filed 2019-02-11 | |||
| 2017-09-30 | -$58.48M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |